AZN Key Statistics, Chart & Performance
The current stock price of AZN is 91 USD. In the past month the price increased by 9.26%. In the past year, price increased by 38.66%.
AZN Latest News, Press Relases and Analysis
AZN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.19 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.64 | 491.06B | ||
| MRK | MERCK & CO. INC. | 11.1 | 244.18B | ||
| PFE | PFIZER INC | 7.82 | 142.37B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.05 | 94.14B | ||
| ZTS | ZOETIS INC | 19.25 | 54.09B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.47 | 22.70B | ||
| VTRS | VIATRIS INC | 4.49 | 12.20B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.18 | 11.05B | ||
| CORT | CORCEPT THERAPEUTICS INC | 87.83 | 8.13B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.46B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.21B |
Related stock screener links
About AZN
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Company Info
ASTRAZENECA PLC-SPONS ADR
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE CB2 0AA GB
CEO: Pascal Soriot
Employees: 94300
Phone: 442073045000
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
What does AZN do?
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
What is the stock price of ASTRAZENECA PLC-SPONS ADR today?
The current stock price of AZN is 91 USD. The price increased by 2.62% in the last trading session.
What is the dividend status of ASTRAZENECA PLC-SPONS ADR?
ASTRAZENECA PLC-SPONS ADR (AZN) has a dividend yield of 1.79%. The yearly dividend amount is currently 2.99.
How is the ChartMill rating for ASTRAZENECA PLC-SPONS ADR?
AZN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists AZN stock?
AZN stock is listed on the Nasdaq exchange.
What is the expected growth for AZN stock?
The Revenue of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 9.58% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for ASTRAZENECA PLC-SPONS ADR?
ASTRAZENECA PLC-SPONS ADR (AZN) has a market capitalization of 282.15B USD. This makes AZN a Mega Cap stock.
AZN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AZN. When comparing the yearly performance of all stocks, AZN is one of the better performing stocks in the market, outperforming 89.41% of all stocks.
AZN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AZN. AZN has an excellent profitability rating, but there are some minor concerns on its financial health.
AZN Financial Highlights
Over the last trailing twelve months AZN reported a non-GAAP Earnings per Share(EPS) of 4.6. The EPS increased by 20.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.17% | ||
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| Debt/Equity | 0.61 |
AZN Forecast & Estimates
33 analysts have analysed AZN and the average price target is 93.08 USD. This implies a price increase of 2.29% is expected in the next year compared to the current price of 91.
For the next year, analysts expect an EPS growth of 13.8% and a revenue growth 9.58% for AZN